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Background: Laparoscopic splenectomy has been proposed to be the standard therapy for adult patients
with medically refractory immune thrombocytopenia (ITP). However, due to inconsistent deﬁnitions of
response, variable rates of long term response have been reported. Furthermore, new medical treatment
options are currently challenging the role of splenectomy. The aims of this study were to (1) analyze long
term response after splenectomy according to recently deﬁned consensus criteria, (2) identify possible
predictive response factors. Methods: A case series of 72 consecutive patients with ITP undergoing
laparoscopic splenectomy was retrospectively studied using univariate and multivariate analysis as well
as logrank tests. Results: Median follow-up was 32 (2e110) months. Mortality was 0% and morbidity was
8.2%. Response to splenectomy was achieved in of 63/72 patients (87.5%). Loss of response occurred in 19/
63 (30.2%) in median after 3 (range 2e42) months. Preoperative platelet counts after boosting with
steroids and immunoglobulins as well as the postoperative rise in platelet counts were statistically
signiﬁcant factors for response upon both univariate and multivariate analysis, whereas age, gender,
body mass index, ASA classiﬁcation, disease duration, accessory spleens, splenic weight, conversion to
open surgery, or perioperative complications were not. Patients with a postoperative rise in platelet
counts >150,000/mL had a signiﬁcant better chance on stable long term response than those with a
smaller increment (P < 0.001). Conclusions: Laparoscopic splenectomy is an effective and safe treatment
option in order to obtain stable long term response in patients with ITP. Perioperative platelet counts are
predictive factors of long term response.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.CR, complete response; R,
SA, American Society of An-
en).
by Elsevier Ltd. All rights reserved1. Introduction
Primary immune thrombocytopenia (ITP), formally known as
idiopathic thrombocytopenic purpura or Morbus Werlhof, is an
acquired autoimmune disorder leading to enhanced thrombocyte
degradation in the reticuloendothelial system. As recently
emerged, a further pathogenic mechanism for ITP is an.
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bone marrow [1]. ITP is deﬁned by a reduced platelet count lower
than 100,000/mL without any other detectable reason [2]. ITP pa-
tients predominantly develop skin andmucosal bleeding, but many
patients remain asymptomatic for long time. Though a major
concern, the total risk for fatal hemorrhagic complications is low
with reported bleeding associated mortality rates of 0.3e10% [3].
The bleeding risk and the hemorrhagic lethality rate increase with
the patient's age [4,5]. In patients with platelet counts lower than
30,000/mL, ﬁrst line medical treatment consists in corticosteroids
[6], possibly in combination with intravenous immune globulins.
Splenectomy is proposed as second line therapy for ITP [6].
Approximately 80% of the patients respond to splenectomy, among
which approximately 66% experience long term remission without
further therapy [7e16]. Therefore, prediction of the hematological
outcome after surgery is important when referring ITP patients for
splenectomy. The laparoscopic approach is advantageous in terms
of shorter hospital stay, less postoperative pain, and lower
complication rates [17e19]; however, hematological outcomes are
not different to conventional splenectomy [8,15,20,21]. Numerous
clinical studies on splenectomy for ITP have been published, but
results are hardly comparable since there is a lack of consensus on
standardized deﬁnitions and outcome criteria. The present study
follows the deﬁnitions and response criteria as stated by the
Vicenza Consensus Conference 2007 [2]. In this conference the
major goal for treatment of ITP was deﬁned as to provide a safe
platelet count rather than correcting the platelet count to normal
levels [2]. Therefore earlier studies on laparoscopic splenectomy for
ITP using older and individual deﬁnitions for remission might give
delusive results. In the light of these differently deﬁned criteria of
response, the aims of this retrospective cohort study were to (1)
analyze long term response after splenectomy according to
consensus criteria, (2) identify possible predictive response factors.
2. Patients and methods
The study was approved by the ethics committee of Muenster
University (AZ 2009-490-f-S). Between 2001 and 2009, 96
consecutive patients underwent laparoscopic splenectomy for
various hematological and oncological disorders at Muenster Uni-
versity Hospital. Among these, 73 patients with medically re-
fractory ITP were identiﬁed. Patient characteristics and
postoperative courses were studied from patient charts and the
clinical data base system retrospectively. 37 patients were males
(50.7%) and 36 (49.3%) females with a mean age of 50.6 ± 19.7 years
(range 16e83) and a body mass index (BMI) of 27.0 ± 4.5 kg/m2
(range 16.6e36.3). Median time from the ﬁrst diagnosis of ITP and
surgery was 11.5 months (range 3 monthse33 years). Indications
for splenectomy included patients who no longer responded to
medical therapy (73/73), those with platelet counts < 10,000/mL
(26/73), and those with recurrent bleeding (58/73; patients
frequently had more than one indication for surgery). Preoperative
medication included steroids (100%, 73/73), immunoglobulins
(52%, 38/73), anti-D (6.8%, 5/73), rituximab (2.7%, 2/73), cyclo-
sporine A (1.3%, 1/73), and azathioprine (1.3%, 1/73). 15 patients
were preoperatively classiﬁed according to the American Society of
Anesthesiologists (ASA) class I (20.6%), 37 patients ASA II (50.7%),
20 patients ASA III (27.4%), and one patient ASA IV (1.3%). All pa-
tients were vaccinated against pneumoccus, menigococcus, and
haemophilus inﬂuenzae perioperatively.
2.1. Surgical procedure
All patients received single shot antibiotic prophylaxis with
cefuroxime 1.5 g i.v. at least 30 min before skin incision.Laparoscopic splenectomy was performed in a standardized three-
trocar technique. After dissection of the colosplenic, gastrosplenic,
and splenophrenical ligaments, the splenic pedicle was divided
with a laparoscopic stapler in accordance to the hanging-spleen-
maneuver [22]. Capsule tearing and spillage of splenic tissue was
carefully avoided. The spleen was removed using an extraction bag
inwhich the spleenwasmorcellated. The entire abdomen including
the lesser sac and the splenic cavity were thoroughly examined for
accessory spleens, which were removed if present. A drainage tube
as an indicator for postoperative bleeding or pancreatic ﬁstula was
placed in left upper quadrant routinely. These tubes were removed
when lipase in the secretion was negative.
2.2. Follow up
Most patients (60.3%, 44/73) had a regular follow up at the
Department of Hematology and Oncology of Muenster University
Hospital. From patients that were followed by their general prac-
titioners (39.7%, 29/73), a written informed consent was obtained
and the follow up datawere inquired from the general practitioners
according to a standardized questionnaire. Hallmarks for follow up
were splenectomy-related mortality and morbidity, post-
splenectomy infections, course of platelet counts, occurrence of
bleeding, and the need for further medical therapy related to
thrombocytopenia.
2.3. Response and relapse criteria
Response and loss of response were related only to the event of
laparoscopic splenectomy and were deﬁned according to recent
consensus criteria [2]:
Complete response (CR) Deﬁned as a normal platelet count of
>100,000/mL at day 30 after splenectomy, and discontinuation of
medication. Spontaneous bleeding must be absent.
Response (R) Deﬁned as a rise in platelet counts > 30,000/mL
and <100,000/mL at day 30 after splenectomy, and at least the
doubling of the baseline platelet count in absence of spontaneous
bleeding, and discontinuation of medication.
Non-response (NR) Deﬁned as a missing rise in platelet
counts > 30,000/mL or an initial rise but return to values < 30,000/
mL within 30 days postoperatively. The need to continue or to
restart medical therapy such as steroids or others to sustain on
normal platelet counts is also considered as non-response. Spon-
taneous bleeding within 30 postoperative days is considered as
non-response.
Loss of response (only patients that initially reached CR or R)
Every thrombocytopenic event with platelet counts < 100,000/mL
(from CR) or < 30,000/mL (from R) or less than 2-fold level of
platelet count compared to baseline (from R) is classiﬁed as a loss of
response. Occurrence of spontaneous bleeding or the need for
medication is also considered as loss of response.
2.4. Potential predictive factors
In order to obtain factors which might inﬂuence the long term
hematological outcome of laparoscopic splenectomy in patients
with ITP, the following variables were implicated for analysis: Age,
gender, BMI, ASA classiﬁcation, duration of the disease (deﬁned as
time from ﬁrst diagnosis until laparoscopic splenectomy), response
to preoperative IgG and/or steroid boosting (reﬂected as platelet
count on admission according to the fact that all patients received a
preoperative boost with IgG and/or steroids), presence of accessory
spleens, splenic weight, conversion to open surgery, perioperative
complications, postoperative rise in platelet counts.
Fig. 1. Overall response [including complete response (CR) and response (R)] after
laparoscopic splenectomy in patients with ITP (KaplaneMeier-curve, n ¼ 72). The y-
axis indicates response levels in percent; the x-axis indicates time after splenectomy in
months. Initial response rate (CR þ R) 1 month after surgery was 87.5%. Approximately
61% of the patients achieved long term response (no loss of response during the
follow-up period of median 32 months). Up to 3.5 years after surgery events of loss of
response were observed, beyond this time point response rate was stable.
E. Rijcken et al. / International Journal of Surgery 12 (2014) 1428e143314302.5. Statistics
For continuous variables with normal distribution, mean and
standard deviation are given, for continuous variables with skewed
distribution median and range are given, respectively. Univariate
statistical evaluations were performed using Fisher's exact test and
t-test where appropriate. Multivariate analysis was performed by
multiple logistic regression analysis. P-values < 0.05 were consid-
ered signiﬁcant. KaplaneMeier curves were created and log rank
tests were performed using SSPS 17.0.
3. Results
A total of 73 patients were included. One patient was discharged
on the ﬁfth postoperative day after an uneventful laparoscopic
splenectomy with a regular postoperative rise in platelet counts,
but the patient was lost to further follow up. Therefore this pa-
tient's data were included in the surgical results (n ¼ 73) but not in
the hematological long term results (n ¼ 72).
3.1. Surgical results
Median operation timewas 123.5 min (range 28e241) including
conversions. Conversion rate was 9.6% (7/73). Reasons for conver-
sionwere bleeding (6/7), severe obesity (3/7), and severe adhesions
after previous surgery (1/7). In most cases a three trocar technique
was used (77%, 56/73) while in 17 patients (23%) an additional
trocar was inserted. Median spleen weight was 145 g (range
70e350). Single or multiple accessory spleens (1e3) were found in
10/73 patients (14%). Pathology results revealed no malignancies or
other speciﬁc ﬁndings. 34/70 (48.6%) specimens showed a hyper-
plasia of the red pulpa and 16/70 (22.9%) a ﬁbrosis of the splenic
capsula. There was no perioperative mortality. Complications
occurred in 6/73 patients (8.2%), which were mostly due to post-
operative bleeding. 5 patients (6.8%) required surgery for bleeding
control. The sources of bleeding were splenic veins in 3 patients,
whereas 2 patients had bleeding from a trocar site in the abdominal
wall. One patient had an epifascial wound infection after conver-
sion. Pancreatic ﬁstulas or intraabdominal abscesses did not occur.
Limited pleural effusion developed in one patient. 9 patients (12%)
were transfused perioperatively (units of erythrocytes: range 0e6
units). Median hospital stay was 6 days (range 3e17). In patients
receiving long term steroids preoperatively, steroids were tapered
quickly after surgery. There were no further postoperative platelet-
speciﬁc or immunosuppressive medications.
3.2. Short term hematological results
Platelet count responses after laparoscopic splenectomy were
observed immediately after the operation. The mean postoperative
platelet count rose from 89,000 ± 72,000/mL preoperatively to
321,000 ± 237,000/mL within 5 days after surgery. Complete
response (CR) was achieved in 56/72 patients (77.8%), whereas
response (R) was observed in 7/72 patients (9.7%). Taking patients
with CR and R together, a total of 63/72 patients (87.5%) responded
after laparoscopic splenectomy according to consensus criteria [2]
However, 9 patients (12.5%) showed non-response (NR).
3.3. Long term hematological results
The duration of follow up for all patients with CR and R (n ¼ 63)
was in median 32 (2e110) months. Among the 56 patients with
initial CR, 18 patients (32.1%) had a loss of response during the
follow up period. One patient with R (1/7, 14.3%) had a loss of
response during follow up. This resulted in a total loss of responserate of 30.2% (19/63). Loss of response occurred in median after 3
(range 2e42) months. The latest loss of response was observed
after 42 months. With regard to these long term results, a total of
44/72 (61.1%) patients had stable remission and no need for further
therapy for ITP after laparoscopic splenectomy. These results are
depicted as a KaplaneMeier curve for all patients in Fig. 1. Esti-
mated endurance of achieved response for all patients was
66.3 ± 5.6% after 1 year, 63.0%, ±5.8% after 2 years, and 60.6% ± 6.0%
after 5 years. In two patients, a documented common cold preceded
the loss of response. One patient developed a lymphoma and one
other patient autoimmune hemolysis before loss of response. None
of the patients experienced splenectomy related mortality or se-
vere infectious events during the follow up period.3.4. Determination of predictive factors for CR and R
Clinical ﬁndings and laboratory data as well surgical results
underwent univariate analysis in relation to the achievement of
response (Table 1). The only parameters with signiﬁcant predictive
value for CR or Rwere response to preoperative steroids and/or IgG
reﬂected as platelet count on admission (P ¼ 0.046) and post-
operative rise of platelet count (P < 0.0001). The same parameters
were analyzed by multivariate multiple logistic regression analysis
(Table 2). Both platelet count on admission (odds ratio 1.353, 95%
conﬁdence interval 1.040e1.761, P ¼ 0.024) and postoperative rise
of platelet count (odds ratio 1.244, 95% conﬁdence interval
1.053e1.470, P ¼ 0.01) were found to be independent predictive
factors for CR and R after laparoscopic splenectomy for ITP. Surgical
complications or conversion to open splenectomy had no effect on
hematological response. We analyzed the platelet counts on
admission as a predictive value for response after splenectomy in
order to predict the duration of response (CR þ R). Patients with
platelet counts on admission <40,000/mL (reﬂecting poor response
to preoperative steroid or IgG boosting) had a signiﬁcant lower rate
of stable response than patients with platelet counts > 40,000/mL
on admission reﬂecting a good response on steroid or IgG boosting
Table 1
Univariate analysis of possible predictive factors for complete response (CR) and
response (R) versus non-response (NR) (n ¼ 72).
Factor CR þ R NR P Value
Age (years) 49.4 ± 19.5 59.9 ± 20 0.171a
Gender (f: m) 32: 31 4: 5 1b
BMI (kg/m2) 26.8 ± 4.4 27.7 ± 4.3 0.57a
ASA (I þ II: III þ IV) 45:18 6: 3 0.714b
Duration of disease (years in
median (range))
0.9 (0.1e25) 0.7 (0.25e33) 0.462a
Thrombocyte count on
admission (103/ml)c
94.1 ± 74.7 60.1 ± 48.8 0.046a
Accessory spleen (y: n) 9: 54 1: 8 1b
Splenic weight (g) 161.3 ± 61.7 148.7 ± 53.7 0.589a
Conversion to open surgery (y: n) 5: 58 2: 7 0.209b
Perioperative complications (y: n) 5: 58 1: 8 0.565b
Postoperative rise of thrombocyte
count (103/ml)
257.1 ± 217.5 30.7 ± 68.0 < 0.0001a
Values given as mean ± standard deviation, if not indicated otherwise.
BMI: Body mass index, ASA: American Society of Anesthesiologists.
Statisically signiﬁcant values are printed in bold.
a t-test.
b Fisher's exact test.
c Reﬂecting the response to preoperative boosting with steroids and/or IgG.
Fig. 2. Platelet count on admission predicts long-term response (CR þ R) after sple-
nectomy (KaplaneMeier-curve, n ¼ 72). The y-axis indicates response levels in
percent; the x-axis indicates time after splenectomy in months. Black curve: platelet
count on admission 40.000/mL (indicating poor response to preoperative boosting),
grey curve: platelet count on admission > 40.000/mL (good response to preoperative
boostering); P ¼ 0.012 (log rank test). Patients with a good response to preoperative
boosting with steroids and/or IgG (increment of thrombocytes > 40.000/ml) have a
better chance to achieve stable long term response after laparoscopic splenectomy.
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<40,000/mL still had a 40% chance to achieve stable response. Un-
fortunately, a separate analysis for different single preoperative
medications was not possible due to the heterogeneity of thera-
peutic regimes. The postoperative rise in platelet counts was found
to be the strongest predictive factor for the achievement of
response (CR þ R). In reﬂection to stable long term response the
postoperative rise in platelet counts was tested using the log rank
method (Fig. 3). Patients with a postoperative rise in platelet counts
>150,000/mL had a signiﬁcantly higher chance to achieve long term
stable response compared to those with a lower rise of platelets
(P < 0.001). Nevertheless, patients with a rise in postoperative
platelet counts of 51,000e150,000/mL still achieved long term sta-
ble response in approximately 50% and those with a rise in post-
operative platelet counts <50,000/mL of approximately 28%.
3.5. Rebound thrombocytosis and thrombotic complications
Reactive or rebound thrombocytosis is generally addressed to as
platelet counts >500,000/ml after splenectomy for any indication. ItTable 2
Multivariate analysis of possible predictive factors for complete response (CR) and
response (R) versus non-response (NR) (n ¼ 72).
Factor OR (Exp (B)) 95% CI P valuea
Age 0.926 0.828e1.036 0.179
Gender (male) 0.459 0.031e6.751 0.57
ASA classiﬁcation 0.32
Duration of disease 1.006 0.990e1.022 0.48
Thrombocyte count on admissionb 1.353 1.040e1.761 0.024
Accessory spleen 11.978 0.167e859.985 0.255
Conversion to open surgery 0.041 0.000e4.140 0.175
Perioperative complications 0.145 0.001e17.969 0.433
Postoperative rise of thrombocyte
count
1.244 1.053e1.470 0.01
Interpretation of Odds ratios:
“Age” e odds ratio for one additional year of lifetime.
“Duration of disease” eodds ratio for one additional month disease duration.
“Thrombocyte count on admission” and “Postoperative rise of thrombocyte count”
e odds ratio for an increment of 10,000/ml, respectively.
OR: Odds ratio, CI: Conﬁdence interval, IgG: Immunoglobulins, ASA: American So-
ciety of Anesthesiologists.
Statisically signiﬁcant values are printed in bold.
a Multiple logistic regression analysis.
b Reﬂecting the response to preoperative boosting with steroids and/or IgG.is observed after medical therapy for ITP as well. 15/72 patients
(20.8%) had rebound thrombocytosis at the time of discharge
(median 711,000/ml, range 530,000e1,000,000/ml). Upon follow-up,
reactive thrombocytosis persisted resp. occurred in 6 patients
(range 693,000e858,000/ml), from which one patient had noFig. 3. Postoperative platelet count (measured during hospital stay) predicts long-
term response (CR þ R) after splenectomy (KaplaneMeier-curve, n ¼ 72). The y-axis
indicates response levels in percent; the x-axis indicates time after splenectomy in
months. Black curve: postoperative platelet counts 0e50.000/mL, dark grey curve:
postoperative platelet counts 51.000e150.000/mL, light grey curve: postoperative
platelet counts >150.000/mL. Patients with a postoperative rise in platelet counts
>150.000/mL have a signiﬁcantly better chance on stable long term response than
those with a smaller rise; P < 0.001 (log rank test).
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after splenectomy occurred in 6 patients (8.3%), although 5/6 had
no thrombocytosis at the time of occurrence. 3 patients experi-
enced deep vein thrombosis, with one developing consecutive
pulmonary embolism. Two patients, both with loss of response,
developed a stroke after media infarction. There were no cases of
postoperative portal or mesenterial vein thrombosis, although
there was no systematic postoperative surveillance program for
this condition. However, one 20-year old patient with post-
operative thrombocytosis and concomitant APC-resistance devel-
oped a BuddeChiari syndrome, leading to successful liver
transplantation 26 months after splenectomy.
4. Discussion
This study shows that laparoscopic splenectomy is a safe pro-
cedure in patients with ITP with no mortality and a low morbidity
rate. Main limitations of this study are its retrospective single
centre design and the inhomogeneity of preoperative medications.
However, long-term response with an increase of quality of life and
discontinuation of medication was achieved by laparoscopic sple-
nectomy in approximately two thirds of our patients. Both preop-
erative response to steroid and IgG boosting (as reﬂected by
preoperative increment of platelet counts) and the postoperative
rise in platelet counts were found to be predictive factors for long
term response after splenectomy. This study uses the consensus
criteria as deﬁned in 2007 and shows that these deﬁnitions are
applicable on surgical studies. Older studies might have to be re-
evaluated according to these deﬁnitions to avoid false impres-
sions on the efﬁcacy of splenectomy in ITP.
When comparing medical and surgical treatment for ITP, it has
to be considered that most patients receiving surgery have already
failed in several medical attempts, causing a bias for therapy-
refractory cases. In adults, long-term remission rates on standard
medical therapy such as corticosteroids or immunoglobulins vary
between 20 and 70% [7,11,23]. However, adverse effects such as
osteoporosis or infections often outweigh their beneﬁts, excluding
corticosteroids as a long term treatment option [6]. 50% of the
patients experience a relapse after discontinuation of steroids [24].
Response rates to rituximab (anti-CD20) were reported to be
44e58% in patients without splenectomy, with a mortality rate of
2.9% in a pooled analysis [25e27]. With the introduction of the
novel thrombopoetin receptor agonists romiplostim and eltrom-
bopag achieving response rates from 38 to 60% [28,29], the indi-
cation for surgical therapy of ITP has to be re-evaluated. However,
thrombopoiesis stimulating drugs might not be a causal therapy for
ITP. Although expectations on these new drugs are high, long term
remission rates and possible side effects have to be awaited for [30].
Economical aspects of long term medical therapy should be also
taken into account.
No response or loss of response after splenectomy occurred in
approximately one third of our patients. This failure rate is higher
than commonly reported in surgical studies. Beside the spleen,
anti-thrombocytic antibodies can be produced in other tissues as
well and thrombocytic breakdown is not limited to the spleen
either; this can lead to persistent thrombocytopeniea despite
splenectomy. Some patients were successfully treated with
immunosuppressive or thrombopoetic medications after loss of
response despite of medically refractory thrombocytopenia before
surgery. This might have been a potential beneﬁt of splenectomy.
However, the reason for loss of response in previously long term
stable patients is not clariﬁed yet.
A major concern is to evaluate risk factors for the failure of
splenectomy in order to identify those patients, which might
beneﬁt from the operation. Although numerous predictive factorssuch as age, response to steroids, duration of the disease, spleen
weight, or postoperative platelet counts have been proposed
[7,10,13,14,16,23,31e34], these factors were not consistently
conﬁrmed. The most cited predictive factors are response to pre-
operative boosting therapy and the postoperative platelet counts.
These factors were also found in this study, which is consistent with
recently published studies [13,14,16]. However, these predictors do
not lead to the decision whether to perform surgery or not, since
patients lacking these predictors still have a reasonable chance of
response. The patients should be informed about their chances of
long term response after surgery, which can be crucial for patients
with a long history of disappointing medical therapies.
Laparoscopic splenectomy is a well evaluated treatment option
with a low complication proﬁle. In a systematic review by Mikhael
et al., splenectomyhasbeenshowntobeeffective forpatientswith ITP
with an approximate failure rate of 28% at ﬁve years [12]. This is
conﬁrmed in the present studywhen applying consensus deﬁnitions.
Therefore splenectomy is still an important option in the treatmentof
patients suffering from ITP, especially in those refractory to medical
therapy.Given the lowriskandthe fact that splenectomy isaone-time
therapy in contrast to repeated antibody infusions, laparoscopic
splenectomy should be discussed with ITP patients by both hema-
tologists and surgeons before escalating medication.
There is no further debate whether splenectomy should be
performed laparoscopically or in an open fashion in patients with
ITP. Although there are no prospective randomized trials available
on this question, the laparoscopic approach is safe in experienced
hands and offers a shorter hospital stay and a good cosmetic result
[15,20,21]. Conversion to open surgery, which is necessary in 0e22
% [12,17,21], does not jeopardize the hematological outcome as
conversion was not a negative predictor. Complications of laparo-
scopic splenectomy in our series were mostly related to bleeding;
however, this is not surprising as 63% of our patients hat platelet
counts <100,000/ml at the time of surgery. On the other hand, there
was no perioperative mortality, showing that the laparoscopic
approach is safe even in patients with severe thrombocytopenia.
5. Conclusion
In summary, laparoscopic splenectomy is still a valuable and
effective option in the treatment of patients with ITP. Uniform
deﬁnitions of response rates do not put the results of former sur-
gical studies in question, since we could conﬁrm long term
response rates in more than 60% of all patients undergoing lapa-
roscopic splenectomy. Identifying patient related predictive factors
of response to either medical or surgical therapy might facilitate
the choice of optimal therapy for the individual patient in the
future.
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